Developing therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …

Antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein
prevent SARS-CoV-2 infection. However, the effects of antibodies against other spike …

Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome–coronavirus 2 (SARS-CoV-2) has now become a pandemic, but there is currently …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged
coronavirus that is responsible for the current pandemic of coronavirus disease 2019 …

COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with
enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can …

The protective human antibody response to severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) focuses on the spike (S) protein, which decorates the virion surface and …

Coronavirus research has gained tremendous attention because of the COVID-19
pandemic, caused by the novel severe acute respiratory syndrome coronavirus (nCoV or …